Thrombotic disorders are the main causeof death and disability in Europe

35%of Male Deaths

43%of Female Deaths

• The innovative in vitro test for evaluating a person’s thrombogenic potential

• Ideal for customising antiplatelet and anticoagulation therapy

• Helps to prevent thrombotic-haemorrhagic disorders

Disorders

Blood clotting is a complex, multifactorial physiological process that allows the body to respond to thrombogenic stimuli (e.g. a blood vessel being damaged). If the body’s physiological response is excessive, a pathologic thrombosis with vessel occlusion and tissue ischaemia may occur leading to myocardial infarctions, strokes, pulmonary embolisms, etc. When a person’s physiological response is insufficient, it may result in excessive bleeding.

Statistic

Thrombotic disorders and cardiovascular diseases such as thrombosis, myocardial infarctions, strokes, embolisms, etc. are the main cause of death and disability in Europe.
In Italy, cardiovascular diseases cause 35% of male deaths and 43% of female deaths. They have a huge impact on public health and weigh heavily on health and economic resources.Spending on cardiovascular surgery is estimated at approximately €650 million. Over €5 billion is spent on medication for these disorders.

Smart Clot

This is an innovative and unique in vitro device that provides, just in few minutes, a semi quantitative dynamic analysis of platelets aggregation and fibrin formation with far greater accuracy than presently possible on the market.

Measuring platelet activation and fibrin formation using a blood sample helps clinicians to chart the thrombogenic potential of a sample and work out a patient’s predisposition to forming thrombi.

In accordance with the new guidelines on the advertisement of medical devices, in vitro medical diagnostic devices and medical surgical devices, published by the Ministry of Health on 28/03/2013, we hereby inform the user that the information contained herein is aimed exclusively at professional operators.